Latest Health Insurance News

Ramsay Health Care delivered stronger FY26 earnings, a higher fully franked dividend and improved Funding Group leverage as it prepares to separate Ramsay Santé. The proposed demerger remains conditional, but the company has set a clear timetable for the next phase of its portfolio reshaping.

Medibank delivered higher FY26 operating profit, underlying earnings and dividends, while its health services arm posted strong growth after the Better Medical acquisition. The annual report also leaves investors weighing cybercrime litigation, capital flexibility and the pace of Medibank Health’s expansion.

Australian Unity Limited (ASX:AYU) posted a statutory loss of $155.2 million for FY2026, reflecting regulatory headwinds, transformation costs, and sector disruptions, while advancing its climate risk management and strategic portfolio adjustments.

nib Group reported a 6.2% revenue increase to $3.8 billion and a 9.1% rise in underlying operating profit to $260.9 million for FY26, despite a 5.9% net profit dip. The company achieved maiden profitability in Health Services and declared a fully franked 21c dividend including a 5c special, supported by ongoing Travel insurance divestments.

Medibank Private Limited reported a 27.5% jump in net profit after tax to $638.7 million for FY26, driven by steady health insurance growth and a 31.3% surge in its Medibank Health segment. The company declared a fully franked final dividend of 10.9 cents per share and updated its Net Zero emissions strategy.

Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

Beamtree Holdings has landed a $2 million contract with Saudi Arabia’s Fakeeh Care Group, while revising down its FY26 ARR growth guidance and outlining cost-cutting measures as part of an ongoing strategic review.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.